PT2902025T - Agente terapêutico para dislipidemia - Google Patents

Agente terapêutico para dislipidemia

Info

Publication number
PT2902025T
PT2902025T PT138423819T PT13842381T PT2902025T PT 2902025 T PT2902025 T PT 2902025T PT 138423819 T PT138423819 T PT 138423819T PT 13842381 T PT13842381 T PT 13842381T PT 2902025 T PT2902025 T PT 2902025T
Authority
PT
Portugal
Prior art keywords
dyslipidemia
therapeutic agent
therapeutic
agent
Prior art date
Application number
PT138423819T
Other languages
English (en)
Inventor
Takizawa Toshiaki
Yoshinaka Yasunobu
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of PT2902025T publication Critical patent/PT2902025T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT138423819T 2012-09-27 2013-09-27 Agente terapêutico para dislipidemia PT2902025T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012214635 2012-09-27

Publications (1)

Publication Number Publication Date
PT2902025T true PT2902025T (pt) 2019-11-04

Family

ID=50387566

Family Applications (1)

Application Number Title Priority Date Filing Date
PT138423819T PT2902025T (pt) 2012-09-27 2013-09-27 Agente terapêutico para dislipidemia

Country Status (21)

Country Link
US (4) US9572798B2 (pt)
EP (1) EP2902025B1 (pt)
JP (1) JP6238460B2 (pt)
KR (1) KR102098032B1 (pt)
CN (1) CN104640544B (pt)
AU (1) AU2013321918B2 (pt)
BR (1) BR112015006305B1 (pt)
CA (1) CA2901650C (pt)
EA (1) EA024873B1 (pt)
ES (1) ES2752039T3 (pt)
HK (1) HK1206620A1 (pt)
IL (1) IL237981B (pt)
IN (1) IN2015DN02966A (pt)
MX (1) MX357446B (pt)
MY (1) MY177686A (pt)
PH (1) PH12015500471A1 (pt)
PL (1) PL2902025T3 (pt)
PT (1) PT2902025T (pt)
SG (1) SG11201501740XA (pt)
TW (1) TWI598098B (pt)
WO (1) WO2014050134A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI691331B (zh) * 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
KR20200019903A (ko) 2017-06-30 2020-02-25 교와 가부시키가이샤 의약 조성물
JP7425603B2 (ja) * 2017-06-30 2024-01-31 興和株式会社 医薬組成物
CN110809470A (zh) * 2017-06-30 2020-02-18 兴和株式会社 医药品
WO2019004465A1 (ja) 2017-06-30 2019-01-03 興和株式会社 ペマフィブラートを含有する医薬
JPWO2019004452A1 (ja) * 2017-06-30 2020-04-30 興和株式会社 医薬組成物
WO2019004450A1 (ja) * 2017-06-30 2019-01-03 興和株式会社 医薬組成物
US11344535B2 (en) 2017-06-30 2022-05-31 Kowa Company, Ltd. Pharmaceutical composition
US20200121648A1 (en) * 2017-06-30 2020-04-23 Kowa Company, Ltd. Pharmaceutical composition
US20190224169A1 (en) * 2017-12-21 2019-07-25 Kowa Company, Ltd. Methods of Treatment of Hypertriglyceridemia
US11446282B2 (en) 2017-12-21 2022-09-20 Kowa Company, Ltd. Methods of treating mixed dyslipidemia and hypertriglycertdemia
JP2020105174A (ja) * 2018-12-27 2020-07-09 興和株式会社 医薬組成物
JP7071538B2 (ja) * 2018-12-27 2022-05-19 興和株式会社 医薬組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002247019C1 (en) 2001-01-26 2017-05-11 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2002347985A1 (en) 2001-11-15 2003-06-10 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
JPWO2005009942A1 (ja) 2003-07-28 2006-09-07 杏林製薬株式会社 光学活性置換フェニルプロピオン酸誘導体
CN100425594C (zh) * 2003-09-03 2008-10-15 兴和株式会社 Ppar活性化化合物及含该化合物的医药组合物
PL1661890T3 (pl) * 2003-09-03 2011-06-30 Kowa Co Związek aktywujący PPAR oraz kompozycja farmaceutyczna zawierająca ten związek
DE102004016845A1 (de) 2004-04-07 2005-10-27 Bayer Healthcare Ag Phenylthioessigsäure-Derivate und ihre Verwendung
CA2581072A1 (en) 2004-09-16 2006-03-30 Merck & Co., Inc. Compounds for the treatment of dyslipidemia and other lipid disorders
TWI359810B (en) 2004-11-04 2012-03-11 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivative containing thiazole rin
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
WO2007008529A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc Celullar cholesterol absorption modifiers
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
CN101583612A (zh) 2006-09-15 2009-11-18 先灵公司 治疗脂质代谢障碍的氮杂环丁酮衍生物
WO2008104875A1 (en) 2007-03-01 2008-09-04 Pfizer Products Inc. Oxazolidinones as cholesterol absorption inhibitors
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及/或治療劑
WO2009047240A1 (en) 2007-10-09 2009-04-16 Smithkline Beecham Corporation Indole derivatives useful as ppar activators
DE102007061757A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung

Also Published As

Publication number Publication date
IL237981B (en) 2020-05-31
MX357446B (es) 2018-07-10
KR102098032B1 (ko) 2020-04-07
IN2015DN02966A (pt) 2015-09-18
TW201417811A (zh) 2014-05-16
KR20150063035A (ko) 2015-06-08
US9931321B2 (en) 2018-04-03
JPWO2014050134A1 (ja) 2016-08-22
ES2752039T3 (es) 2020-04-02
CA2901650A1 (en) 2014-04-03
US9572798B2 (en) 2017-02-21
EP2902025A4 (en) 2016-03-02
US10258609B2 (en) 2019-04-16
PH12015500471B1 (en) 2015-04-20
EA201590653A1 (ru) 2015-07-30
MX2015003705A (es) 2015-06-10
US11013722B2 (en) 2021-05-25
JP6238460B2 (ja) 2017-11-29
BR112015006305B1 (pt) 2020-11-17
MY177686A (en) 2020-09-23
US20170112811A1 (en) 2017-04-27
HK1206620A1 (en) 2016-01-15
CN104640544A (zh) 2015-05-20
IL237981A0 (en) 2015-05-31
TWI598098B (zh) 2017-09-11
PH12015500471A1 (en) 2015-04-20
WO2014050134A1 (ja) 2014-04-03
EP2902025B1 (en) 2019-08-07
SG11201501740XA (en) 2015-04-29
EA024873B1 (ru) 2016-10-31
AU2013321918A1 (en) 2015-04-23
CA2901650C (en) 2021-05-04
CN104640544B (zh) 2017-05-03
AU2013321918B2 (en) 2018-05-10
US20190167645A1 (en) 2019-06-06
BR112015006305A2 (pt) 2017-07-04
US20150196538A1 (en) 2015-07-16
EP2902025A1 (en) 2015-08-05
PL2902025T3 (pl) 2020-03-31
US20180185337A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
HK1203963A1 (en) Novel therapeutic agents
GB201212513D0 (en) Therapeutic agents
HK1206620A1 (en) Therapeutic agent for dyslipidemia
EP2867209A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USES
EP2823830A4 (en) MESH-HIGHNESS MEDIUM
GB201217439D0 (en) Combination therapy
GB201217704D0 (en) Therapeutic agents
PL2723330T3 (pl) Lek kombinowany zawierający środek naczynioskurczowy
HK1219224A1 (zh) 角結膜病症的治療劑
EP2821073A4 (en) CIRCADIAN RHYTHM IMPROVEMENT AGENT
GB201207305D0 (en) Therapy
GB201420971D0 (en) Therapeutic composition
HK1210426A1 (en) Combination therapy
EP2914267A4 (en) TREATMENT OF DARM CONSTIPATION
HK1219662A1 (zh) 血脂異常症治療劑
EP2804853A4 (en) THERAPEUTIC USES
IL236873A0 (en) therapeutic compounds
ZA201405764B (en) Novel therapeutic agents
GB201223021D0 (en) Therapeutic agents
GB201214985D0 (en) Modified therapeutic agents
GB201213712D0 (en) Modified therapeutic agents
GB201212512D0 (en) Therapeutic agents
GB201210233D0 (en) Therapeutic agents
GB201213192D0 (en) Support for therapeutic
GB201211528D0 (en) Therapeutic apparatus